Validation for Prostate Cancer

RNS Number : 9296R

Angle PLC

11 November 2011

 



For immediate release

11 November 2011

ANGLE plc ("the Company")

Parsortix Update

VALIDATION FOR PROSTATE CANCER   

ANGLE plc (AIM : AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved another important milestone by confirming that its cell separation device can capture prostate cancer cells.

ANGLE has previously established that its Parsortix separation technology can capture breast cancer cells added to blood.  New experiments have now shown that the Parsortix separation technology works equally well with cultured prostate cancer cells added to blood.

This new validation is an important step towards demonstrating that, unlike existing antibody affinity based technology, the Parsortix separation technology works well with any solid tumour cancers without the need for modification.

The Parsortix separation technology offers the potential for a CTC (circulating tumour cell) isolation, capture and characterisation device, for: 

·     early detection of cancer;

·     monitoring of cancer patients during treatment; and

·     post-treatment monitoring of cancer patients in remission.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Adrian Hargrave (Nominated adviser) Andy Roberts (Sales)	020 7397 8900
Buchanan Lisa Baderoon	020 7466 5000
Scott Harris Stephen Scott, James O'Shaughnessy, Harry Dee	0207 653 0030

 

END

 

 

MSCEAKFFFLKFFEF